Anti-COVID-19 antibody responses are attenuated in patients who receive infliximab for inflammatory bowel disease, according to a speaker at the 2021 Interdisciplinary Autoimmune Summit.

“Besides long-haul COVID-19, what I think is going to be another major aspect going forward is the issue of whether or not our medications impact on the antibody response to the virus,” Stephen B. Hanauer, MD, professor of medicine at the Northwestern University Feinberg School of Medicine, and medical director of the Northwestern Medicine Digestive Health Center, in Chicago, told attendees at the

Full Article: